Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ZIOPHARM Oncology, a biopharmaceutical company, has announced that an Independent Data Monitoring Committee (IDMC) has recommended the continuation of Phase III study of Palifosfamide in metastatic soft tissue sarcoma.
Subscribe to our email newsletter
The IDMC reviewed all available study data and determined that the trial should continue as designed and conducted, which is the third such review and recommendation by the committee.
Targeted completion of enrollment for PICASSO 3 is expected by the end of the first quarter of 2012, the company said.
The study’s primary endpoint for accelerated approval, the outcome in progression-free survival, is expected in the second half of 2012.